Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 12/20 | 1.00 |
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CETP | P11597 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CXCR5 | P32302 | 2/20 | 1.00 |
| ▸ | CCR6 | P51684 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | UBE2N | P61088 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sphingosine SCHEMBL6348073 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| Sphingosine SCHEMBL2306197 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL14378962 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| Sphingosine SCHEMBL22911044 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL22986843 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL21428474 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL22986939 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL20819097 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| Sphingosine SCHEMBL21114357 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL21428477 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111904904-A | Multi-effect moistening and nourishing mask formula and preparation method | 江苏远恒药业有限公司 | 2020-11-10 | — | — | CN | claimed |
| EP-2134315-B1 | TATTOO-REMOVING COMPOSITION | SK AGELESS CONCEPT GMBH (DE) | 2016-11-09 | — | — | EP | claimed |
| WO-2016161360-A1 | EFFECTIVE HAIR STYLING COMPOSITIONS AND PROCESSES | NUTECH VENTURES (US) | 2016-10-06 | — | — | WO | claimed |
| EP-2300030-A2 | RICE BRAN EXTRACTS AND METHODS OF USE THEREOF | Rice Science, Llc (US) | 2011-03-30 | — | — | EP | claimed |
| US-20100119466-A1 | TATTOO-REMOVING COMPOSITION | SK AGELESS CONCEPT GMBH (DE) | 2010-05-13 | — | — | US | claimed |
| US-20100015258-A1 | Rice Bran Extracts and Methods of Use Thereof | HALPERN, BARUCH | 2010-01-21 | — | — | US | claimed |
| EP-2134315-A1 | TATTOO-REMOVING COMPOSITION | SK ageless-concept GmbH (DE) | 2009-12-23 | — | — | EP | claimed |
| WO-2009143065-A2 | RICE BRAN EXTRACTS AND METHODS OF USE THEREOF | RICE SCIENCE, LLC (US) | 2009-11-26 | — | — | WO | claimed |
| WO-2008128514-A1 | TATTOO-REMOVING COMPOSITION | FAGRON GROUP B.V. (NL) | 2008-10-30 | — | — | WO | claimed |
| WO-2026099472-A1 | LIPOSOMAL COMPOSITIONS FOR TREATMENT OF INFLAMMATION | Universität Bern (CH) | 2026-05-15 | — | — | WO | disclosed |
| US-20260069697-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12496345-B2 | Method of treating cancer | INTENSITY THERAPEUTICS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4634230-A1 | ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF INFECTIONS CAUSED BY ENVELOPED VIRUSES | Fundació Privada Institut de Recerca de la SIDA-Caixa (ES) | 2025-10-22 | — | — | EP | disclosed |
| EP-4624449-A1 | VEGETABLE OIL CERAMIDES, SYNTHESIS METHOD THEREFOR, AND USE THEREOF | Shenzhen Dikeman Biotechnology Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| EP-0940140-A1 | Topical composition of alpha hydroxy acids and ceramides for the treatment of skin conditions | Laboratoire D'Evolution Dermatologique (L.E.D.) (FR) | 1999-09-08 | — | — | EP | disclosed |
| US-5677472-A | PURIFICATION, ISOLATION PHOSPHATIDES BY SOLVENT EXTRACTION THE FAT | SVENSKA MEJERIERNAS RIKSFOERENING EKONOMI AB (SE) | 1997-10-14 | — | — | US | disclosed |
| US-5534553-A | Drug containing fatty amino alcohols or derivatives thereof | HOERRMANN WILHELM (DE) | 1996-07-09 | — | — | US | disclosed |
| EP-0689579-A1 | METHOD FOR EXTRACTING SPHINGOMYELIN | SVENSKA MEJERIERNAS RIKSFORENING EKONOMI AB (SE) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994018289-A1 | METHOD FOR EXTRACTING SPHINGOMYELIN | SVENSKA MEJERIERNAS RIKSFÖRENING EKONOMI AB (SE) | 1994-08-18 | — | — | WO | disclosed |
| US-5220043-A | Synthesis of D-erythro-sphingomyelins | OHIO UNIVERSITY (US) | 1993-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496345-B2 | Method of treating cancer | PBK, GZMB, NPC1L1 | SPHK2 49/4885SPHK1 45/4885MAPT 3903/4885 |
| US-20260069697-A1 | METHOD OF TREATING CANCER | PBK, GZMB, KLRK1 | SPHK2 117/4885SPHK1 236/4885MAPT 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.